InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by FONTEYNE PAUL R., Director. Officer active across 5 companies, notably Apellis Pharmaceuticals, Inc.. Aggregated, 9 disclosures have been published. Total volume traded: €331k. The latest transaction was disclosed on 6 January 2022 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations9 total
30,666 shares
Common Stock
SEC:0001193125-26-224618·
30,666 shares
Common Stock
SEC:0001193125-26-224618:0·
53,832 shares
Common Stock
SEC:0001104659-22-057532:0·
€66,2863,947 shares@ €16.7941100.0% of flow
Common Stock
SEC:0000899243-22-001527·
Ideal exit: 3 Oct 2022 (T+270)
€66,2863,947 shares@ €16.79410.0045% mcap50.0% of flow
Common Stock
SEC:0000899243-22-001527:0·
Ideal exit: 3 Oct 2022 (T+270)
04,230 shares0
Common Stock
SEC:0001127602-22-000726·
04,230 shares0
Common Stock
SEC:0001127602-22-000726:0·
€99,1195,000 shares@ €19.8237100.0% of flow
Common Stock
SEC:0001752836-21-000236·
Ideal exit: 7 May 2022 (T+270)
€99,1195,000 shares@ €19.823750.0% of flow
Common Stock
SEC:0001752836-21-000236:0·
Ideal exit: 7 May 2022 (T+270)
9 of 9 declarations
About FONTEYNE PAUL R.
Paul R. Fonteyne is a Director of Apellis Pharmaceuticals, Inc. and COVETRUS, INC. He plays a key role in the governance of these companies and in strategic decision-making.
